PT2406280E - Materiais biológicos e utilizações dos mesmos - Google Patents

Materiais biológicos e utilizações dos mesmos Download PDF

Info

Publication number
PT2406280E
PT2406280E PT107221608T PT10722160T PT2406280E PT 2406280 E PT2406280 E PT 2406280E PT 107221608 T PT107221608 T PT 107221608T PT 10722160 T PT10722160 T PT 10722160T PT 2406280 E PT2406280 E PT 2406280E
Authority
PT
Portugal
Prior art keywords
biological materials
biological
materials
Prior art date
Application number
PT107221608T
Other languages
English (en)
Inventor
Kim Suzanne Midwood
Brian Maurice John Foxwell
Original Assignee
Imp Innovations Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imp Innovations Ltd filed Critical Imp Innovations Ltd
Publication of PT2406280E publication Critical patent/PT2406280E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Rehabilitation Therapy (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
PT107221608T 2009-03-13 2010-03-15 Materiais biológicos e utilizações dos mesmos PT2406280E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0904355.5A GB0904355D0 (en) 2009-03-13 2009-03-13 Biological materials and uses thereof

Publications (1)

Publication Number Publication Date
PT2406280E true PT2406280E (pt) 2014-08-28

Family

ID=40637300

Family Applications (1)

Application Number Title Priority Date Filing Date
PT107221608T PT2406280E (pt) 2009-03-13 2010-03-15 Materiais biológicos e utilizações dos mesmos

Country Status (18)

Country Link
US (1) US20130045212A1 (pt)
EP (3) EP2754668B1 (pt)
JP (1) JP5847590B2 (pt)
CN (1) CN102712686B (pt)
AU (2) AU2010222708B2 (pt)
BR (1) BRPI1009819A2 (pt)
CA (1) CA2754945C (pt)
CY (1) CY1115463T1 (pt)
DK (1) DK2406280T3 (pt)
ES (1) ES2491617T3 (pt)
GB (1) GB0904355D0 (pt)
HK (1) HK1199888A1 (pt)
HR (1) HRP20140710T1 (pt)
PL (1) PL2406280T3 (pt)
PT (1) PT2406280E (pt)
SI (1) SI2406280T1 (pt)
SM (1) SMT201400120B (pt)
WO (1) WO2010103289A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180022792A9 (en) * 2009-03-13 2018-01-25 Karen Foxwell Biological Materials and Uses Thereof
CA2894746A1 (en) * 2011-12-12 2013-06-20 Isis Innovation Limited Biomarker and use thereof
EP2847215A1 (en) * 2012-05-07 2015-03-18 Synthes GmbH Methods and devices for treating intervertebral disc disease
CA2936159A1 (en) * 2014-01-13 2015-07-16 Imperial Innovations Limited Biological materials and therapeutic uses thereof
GB201414021D0 (en) * 2014-08-07 2014-09-24 Nascient Ltd Biological materials and uses thereof
GB201517184D0 (en) * 2015-09-29 2016-02-10 Imp Innovations Ltd Biological materials and uses thereof
GB201602414D0 (en) * 2016-02-10 2016-03-23 Nascient Ltd Biological materials and uses thereof
GB201616596D0 (en) * 2016-09-29 2016-11-16 Nascient Limited Epitope and antibodies

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB9122820D0 (en) * 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
US6124260A (en) * 1998-09-30 2000-09-26 Cedars-Sinai Medical Center Inhibition of smooth muscle cell migration by Tenascin-C peptides
JP3646159B2 (ja) * 2001-02-08 2005-05-11 国立大学法人三重大学 抗テネイシンｃモノクローナル抗体及び当該抗体を産生するハイブリドーマ
AU2003258134A1 (en) * 2002-08-09 2004-02-25 Applera Corporation Lung cancer target proteins and use thereof
JP2004217546A (ja) * 2003-01-10 2004-08-05 Japan Science & Technology Agency 標識化抗テネイシンｃモノクローナル抗体
WO2005009366A2 (en) * 2003-07-24 2005-02-03 Cornell Research Foundation, Inc. Restoring vascular function
WO2008154008A1 (en) * 2007-06-11 2008-12-18 The Scripps Research Institute Methods and compositions for inhibiting toll-like receptor mediated immune responses

Also Published As

Publication number Publication date
JP5847590B2 (ja) 2016-01-27
EP2406280B1 (en) 2014-05-14
SI2406280T1 (sl) 2014-09-30
US20130045212A1 (en) 2013-02-21
CA2754945C (en) 2020-03-10
BRPI1009819A2 (pt) 2016-11-16
AU2010222708B2 (en) 2014-07-24
JP2012520278A (ja) 2012-09-06
CN102712686B (zh) 2017-10-17
CA2754945A1 (en) 2010-09-16
EP2754668A3 (en) 2014-07-30
EP3392269B1 (en) 2021-10-27
AU2014213514B2 (en) 2016-07-14
HK1199888A1 (en) 2015-07-24
GB0904355D0 (en) 2009-04-29
ES2491617T3 (es) 2014-09-08
HRP20140710T1 (hr) 2014-09-26
DK2406280T3 (da) 2014-07-28
EP2406280A1 (en) 2012-01-18
AU2014213514A1 (en) 2014-09-04
AU2010222708A1 (en) 2011-10-06
SMT201400120B (it) 2014-11-10
CN102712686A (zh) 2012-10-03
PL2406280T3 (pl) 2014-11-28
WO2010103289A1 (en) 2010-09-16
CY1115463T1 (el) 2017-01-04
EP2754668A2 (en) 2014-07-16
EP3392269A1 (en) 2018-10-24
EP2754668B1 (en) 2018-05-09

Similar Documents

Publication Publication Date Title
ZA201107486B (en) Anti-tnf-x antibodies and their uses
LT3222617T (lt) Psma nukreipti junginiai ir jų naudojimas
EP2515822A4 (en) DISPOSABLE CONTAINER AND ITS USE
EP2494062A4 (en) ANTI-GLP-1R ANTIBODIES AND THEIR USES
GB201011771D0 (en) Biological material and particular uses thereof
HK1150614A1 (en) Biological materials and uses thereof
EP2437052A4 (en) BIOSENSOR AND USE THEREOF
HK1199888A1 (en) Biological materials and uses thereof
IL215291A0 (en) NOVEL ANTI-a5BETA1 ANTIBODIES AND USES THEREOF
GB0904825D0 (en) Biological materials and uses thereof
IL220536A0 (en) Anti - bv8 antibodies and uses thereof
GB201002082D0 (en) Biological material
GB0701062D0 (en) Biological materials and uses thereof
IL214527A0 (en) Anti-mst1r antibodies and uses thereof
GB0909768D0 (en) Novel compounds and uses thereof
SI2246181T1 (sl) Kompozitni material in njegova uporaba
GB0811362D0 (en) Biological materials and uses thereof
GB0922143D0 (en) Biological materials and uses thereof
GB0802980D0 (en) Biological materials and uses thereof
GB0906115D0 (en) Antibody and uses thereof
GB0802075D0 (en) Biological materials and uses thereof
GB0808956D0 (en) biological materials and uses thereof
GB201009307D0 (en) Biological materials and uses thereof
GB201011770D0 (en) Biological material and there uses thereof
GB0711926D0 (en) Biological materials and uses thereof